Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gregory Durm"'
Autor:
Maitri Kalra, Elizabeth Henry, Kelly McCann, Meghan S Karuturi, Jean G Bustamante Alvarez, Amanda Parkes, Robert Wesolowski, Mei Wei, Sarah S Mougalian, Gregory Durm, Angel Qin, Caitlin Schonewolf, Meghna Trivedi, Avan J Armaghani, Frederick H Wilson, Wade T Iams, Anita A Turk, Praveen Vikas, Michael Cecchini, Sam Lubner, Priyadarshini Pathak, Kristen Spencer, Vadim S Koshkin, Matthew K Labriola, Catherine H Marshall, Katy E Beckermann, Marina N Sharifi, Anthony C Bejjani, Varsha Hotchandani, Samir Housri, Nadine Housri
Publikováno v:
JMIR Cancer, Vol 8, Iss 2, p e33859 (2022)
BackgroundExpert knowledge is often shared among multidisciplinary academic teams at tumor boards (TBs) across the country, but these conversations exist in silos and do not reach the wider oncology community. ObjectiveUsing an oncologist-only quest
Externí odkaz:
https://doaj.org/article/b5128dc2db1f4f718a05df5e4722645d
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Over the past decade, lung cancer treatment has undergone a major paradigm shift. A greater understanding of lung cancer biology has led to the development of many effective targeted therapies as well as of immunotherapy. Immune checkpoint inhibitors
Externí odkaz:
https://doaj.org/article/66d47352024c453cba50a880c4c33b85
Autor:
Kaustabh Sarkar, Sandra Torresgrossa-Allen, Mark P. Langer, Gregory Durm, Sanjeev Narayanan, Bennett D. Elzey, You-Yeon Won
Publikováno v:
Cancer Research. 82:304-304
Head and neck squamous cell carcinoma (HNSCC) is the 8th most common cancer in the United States predominantly affecting people over 65 years of age with an increasing rate of incidence across the world. Current therapies for HNSCC include surgical r
Autor:
David Gandara, Kristen Marrone, Ramaswamy Govindan, Ferdinandos Skoulidis, Gregory Durm, Jeffrey Clarke, Richard Frank, John Krauss, Wendy Snyder, Tian Dai, Omar Mather, Paul Cifuentes, Antreas Hindoyan, Abraham Anderson, Timothy Burns
Publikováno v:
Molecular Cancer Therapeutics. 20:P05-02
Background: Sotorasib, a specific, irreversible KRASG12C inhibitor, was recently FDA-approved for adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who received prior systemic therapy. The multi-arm phase 1b CodeBreaK101 master stu
Autor:
Liang Cheng, Patrick J. Kiel, PharmD, Bcps, Bcop, Anna Livers-Ertel, Anp-Bc, Msn, Ocn, Gregory Durm
Publikováno v:
Journal of the Advanced Practitioner in Oncology. 8